Drop in biological initiation for patients with psoriasis during the COVID‐19 pandemic

Penso, Laëtitia; Dray‐Spira, Rosemary; Weill, Alain; Zureik, Mahmoud; Sbidian, É.

doi:10.1111/bjd.20406

Cited by 11 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, a decrease of up to 57% was observed in the initiation of biologics for psoriasis healthcare users during the first lockdown (March to May) in France, much higher than the one we observed during the second wave. 20 At the same time, patients already treated with biologics and nonbiologic systemic treatments maintained their treatments during the pandemic. 20 Cumulative reassuring data on the use of biologics during the COVID-19 pandemic may have changed patients' risk-mitigating and clinicians' prescription behaviours.…”

Section: Discussionmentioning

confidence: 99%

“…20 At the same time, patients already treated with biologics and nonbiologic systemic treatments maintained their treatments during the pandemic. 20 Cumulative reassuring data on the use of biologics during the COVID-19 pandemic may have changed patients' risk-mitigating and clinicians' prescription behaviours. A wider exposure to COVID-19 may have led to a similar risk of hospitalization for COVID-19 for individuals exposed to biologics than no biologics.…”

Section: Discussionmentioning

confidence: 99%

“…27 Change in treatment advice was also observed with a decrease of up to 57% in the initiation of biologics for psoriasis healthcare users during the first lockdown. 20 Thus patients' risk-mitigating behaviours may have changed during the second part of the pandemic with a wider exposure to COVID-19.…”

Section: Study Population and Follow-up Proceduresmentioning

confidence: 99%

“…17 Despite the preliminary reassuring data, we observed a marked decrease of up to 60% in initiation of biologics for psoriasis during the first lockdown for COVID-19 in France (from March to May 2020), which was not compensated for during the following months. 20 To ensure continuity of care for psoriasis, this study aimed to provide data assessing the risk of hospitalization or inhospital mortality due to COVID-19 by treatment exposure in patients with psoriasis, taking into account modifications of medical care over time.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France

Penso

Dray‐Spira

Weill

et al. 2022

British Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Study Population and Follow-up Proceduresmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France

Penso

Dray‐Spira

Weill

et al. 2022

British Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…2,3 Patient attitude about receiving treatment also changed during this period due to either healthcare access difficulties or concern on the safety of these drugs. 4,5 In Turkey, patients were able to receive their previously prescribed biologics during EC and LC period owing to regulations for lowering hospital admissions. We think follow-up reduction was caused mainly by this regulation.…”

Section: Proportions Of Patients Who Started Biologics In All Biologic Usersmentioning

confidence: 99%

Effect of COVID‐19 pandemic on psoriatic patients dermatology admissions and biologic treatment adherences: A single‐center retrospective study

Özdemir

Hayran

Şen

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting

Ghoreishi Amin,

Khosravi,

Atefi

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionThis systematic review and meta‐analysis aims to investigate the mutual impact of COVID‐19 and psoriasis to inform clinical practice and future research.MethodsWe followed the Preferred Reporting Items for Systematic Reviews and Meta‐analysis protocol for systematic reviews and searched PubMed, Web of Science, Scopus, and Google Scholar until May 1, 2022. Eligibility criteria included full‐text articles in English reporting COVID‐19 treatment outcomes in psoriasis patients. Studies on animals, letters to editors, non‐English studies, and studies with no access to full articles were excluded. Search results were screened and data were extracted by two groups of reviewers with any discrepancies resolved by the senior author. The risk of bias was assessed using ROBINS‐I for nonrandomized studies. The hospitalization rate, Intensive Care Unit (ICU) admission rate, case fatality rate, odds ratios of COVID‐19 infection and hospitalization rate in psoriasis patients were extracted and analyzed using random effects analysis to calculate pooled prevalence and odds ratios, as well as to explore heterogeneity.ResultsWe found 1980 records from four databases and included 20 studies after screening and removing duplicates. These studies evaluated 185,000 psoriasis patients and included eight retrospective cohort studies, one case‐control study, three cross‐sectional studies, and eight case series studies. The impact of the COVID‐19 pandemic on psoriasis treatment and the outcome of COVID‐19 infection in psoriasis patients receiving different forms of treatment were evaluated. The pooled data from included studies showed that the incidence rate of COVID‐19 infection among psoriasis patients was 0.03% (confidence interval [CI]: 0.01–0.06), with a pooled odds ratio of 1.97 (CI: 0.69–5.60) compared to the general population. The hospitalization rate, ICU admission rate, and case fatality rate for psoriasis patients with COVID‐19 were 0.17 (CI: 0.10–0.31), 0.06 (CI: 0.06–0.46), and 0.02 (CI: 0.01–0.04), respectively. Additionally, psoriasis patients receiving systemic nonbiologic therapy had a pooled odds ratio of 2.32 (CI: 1.18–4.57) for hospitalization compared to those using biologic agents.ConclusionStudies have shown that biologic therapy for psoriasis did not increase the risk of hospitalization due to COVID‐19 infection and may have even offered some protection. Treatment adherence was higher in psoriasis patients receiving biologic therapies than those receiving conventional therapies. These findings suggest that psoriasis treatment did not negatively impact COVID‐19 infection and that treatment could be continued on a case‐by‐case basis during the pandemic.

show abstract

Drop in biological initiation for patients with psoriasis during the COVID‐19 pandemic

Cited by 11 publications

References 7 publications

Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France

Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France

Effect of COVID‐19 pandemic on psoriatic patients dermatology admissions and biologic treatment adherences: A single‐center retrospective study

A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting

Contact Info

Product

Resources

About